Kyverna Therapeutics, Inc.
kyvernatx.comWhat Do They Do?
Develops immune-cell therapies for people with autoimmune diseases, including stiff person syndrome and generalized myasthenia gravis.
10-K for FY2025, filed Mar 26, 2026We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our…View ↗
We are currently focused on advancing our neuroimmunology CAR T franchise, which includes evaluating miv-cel in stiff person syndrome, or…View ↗
SPS is a rare and progressive neurologic autoimmune disease with no FDA-approved therapies. Patients with SPS have substantial disease…View ↗
Myasthenia gravis, or MG, is a B-cell and antibody-mediated neuromuscular autoimmune disease that causes fluctuating muscle weakness and…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$38.3MView ↗
- ▼ −9% (Loss)
- vs −$42.1M in Q2 FY2025
-
May 18, 2026
Kyverna appointed a new chief financial officer
Greg Martini succeeded Marc Grasso, who will consult during the transition.
Sources
8-K, filed May 18, 2026
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the…View ↗
Who Do They Compete With?
Competes with Roche Holding, AbbVie, Johnson & Johnson, Bristol Myers Squibb, Novartis, Cabaletta Bio, and Cartesian Therapeutics
10-K for FY2025, filed Mar 26, 2026Companies developing biologics and other modalities include Roche Holding AG (currently markets Rituxan (rituximab), which is used for a…View ↗
Loading...
